Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT596

Cell therapy (CAR-NK) · Kills target cells, directed at CD19 · developed by Fate Therapeutics

Phase 1 Most advanced trial (none active)
FATE Developer
1 Registered trials

What is FT596?

FT596 is an allogeneic, iPSC-derived CAR-NK cell product engineered to express an anti-CD19 chimeric antigen receptor, a high-affinity non-cleavable CD16 Fc receptor, and an IL-15/IL-15 receptor alpha fusion. It recognizes and kills CD19-expressing tumor cells and can enhance antibody-dependent cellular cytotoxicity with co-administered monoclonal antibodies. It is studied in B-cell lymphoma and chronic lymphocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-NK)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Pathways
antibody-dependent cellular cytotoxicity, NK cell activation and cytokine secretion
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04245722 Phase 1 Lymphoma, B-Cell Terminated FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Lymphocytic LeukemiaLymphoma, B-Cell

Other drugs acting on CD19

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT596

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.